Atlas Trials

Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase

Clinical trial NCT00220389 · COMPLETED

Trial details

NCT number
NCT00220389
Sponsor
Pfizer
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Overactive Bladder
Start date
2003-06-01
Primary completion
2007-06-01

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.